ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
51 announcements with these filters
Laurus Labs allotted 3,93,001 equity shares following the exercise of employee stock options. The company realized ₹12.40 Crore from the allotment across four ESOP grant schemes.
Laurus Labs debuted in the Dow Jones Best-in-Class (DJ BIC) World Index. This recognition highlights the company's strong ESG performance and ethical corporate governance commitment.
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs Limited announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms effective July 2026. Additionally, Mrs. Aruna Bhinge will complete her tenure as Director on July 6, 2026. These board changes bring extensive scientific and financial expertise to the company's leadership.
Laurus Labs Limited declared an interim dividend of ₹1.2 per equity share for FY 2025-26. The board fixed May 8, 2026, as the record date, with payment scheduled to be completed by May 20, 2026.
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs has appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms effective July 02, 2026. Simultaneously, the company announced the retirement of Independent Director Mrs. Aruna Bhinge effective July 06, 2026, upon completion of her second term.
Laurus Labs Ltd has approved the voluntary closure of its non-material German subsidiary, Laurus Generics GmbH. The subsidiary reported nil turnover for FY 2025-26 and its closure is expected to have no material impact on the company's consolidated financials.
Laurus Labs approved an additional investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support KRKA's capital expenditure for setting up a manufacturing facility. The company's shareholding in the JV will remain unchanged at 49%.
Laurus Labs approved the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Additionally, Mrs. Aruna Bhinge will retire as an Independent Director on July 06, 2026, upon completing her second term.
Laurus Labs Limited has declared a 2nd Interim Dividend of Rs.1.20 (60%) per equity share for FY 2025-26. The company has fixed May 08, 2026, as the record date. The dividend payment will be made on or after May 20, 2026.
Laurus Labs announced its FY26 results, reporting ₹6,813 Crore in revenue with a 23% year-on-year growth. EBITDA reached ₹1,826 Crore with 26.8% margins, driven by strong CDMO performance and a better product mix. The company declared a second interim dividend of ₹1.2 per share and continues major CAPEX investments for future growth.
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.
Laurus Labs approved an investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support the setup of a manufacturing facility. Additionally, the company announced two independent director appointments and the voluntary closure of its step-down German subsidiary.
Laurus Labs Ltd reported revenue from operations of ₹1,812 Cr (+5.3% YoY) and net profit of ₹282.1 Cr (+21.2% YoY) for Q4 FY26.
Laurus Labs Limited reported audited consolidated financial results for FY 2025-26, with annual total income reaching ₹6,867.85 Crore. The Board approved a second interim dividend of ₹1.20 (60%) per equity share for FY 2025-26, with a record date of May 08, 2026. The 21st AGM is scheduled for July 02, 2026.
Laurus Labs Limited clarified deficiencies in its October 23, 2025 financial results submission. The company addressed technical issues regarding machine-readable formats and XBRL discrepancies due to portal glitches. It confirmed that revised and correct XBRL filings have been submitted to the exchange to rectify the inadvertent selection of half-yearly figures.
Laurus Labs Ltd reported net profit of ₹252 Cr (+171.3% YoY) for Q3 FY26.
Laurus Labs Limited has scheduled a board meeting for April 30, 2026, to consider audited financial results for the year ended March 2026 and an interim dividend. The trading window for designated persons is closed from April 1, 2026, until May 2, 2026.
Laurus Labs Ltd has scheduled a Board meeting on April 30, 2026, to approve audited financial results for FY26 and consider a second interim dividend. The company's trading window is closed from April 01 to May 02, 2026.
Laurus Labs announced that unsecured creditors of its subsidiaries, Laurus Synthesis and Sriam Labs, have approved a Composite Scheme of Arrangement. This approval marks a significant milestone in the restructuring process. The scheme remains subject to final approval from the NCLT and other regulatory authorities.